retatrutide mechanism glp-1 gip glucagon triple agonist Retatrutide—A Game Changer in Obesity Pharmacotherapy retatrutide triple agonist glp-1 gip

Read Retatrutide vs Semaglutide

Approval for Diabetes and Weight Management Over the past decade, three GLP-1/GIP receptor agonists liraglutide, semaglutide, and tirzepatide initially approved by the FDA for adults with type 2 diabetes, have also gained FDA approval for chronic weight management in people without diabetes, provided they meet specific criteria: a BMI of 30, or 27 with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes

LPL is also a key player in the transport of fats to the cells that need the fat for fuel, particularly muscle cells

Regardless of the method, the study found, people who lost more weight had greater decreases in testosterone levels